RedHill Releases ‘Positive’ Results From Early Covid-19 Trial With Opaganib; Shares Drop 5.6%
RedHill Biopharma Ltd. said that preliminary data results from the
US Phase 2 study of its opaganib administered in patients
hospitalized with COVID-19 pneumonia demonstrated positive safety
and efficacy signals. Meanwhile, shares closed 5.6% lower on Dec.
31. RedHill Biopharma (RDHL) reported that the findings of the
Phase 2 study of 40 hospitalized patients requiring oxygen support
demonstrated that opaganib was safe, with no material safety
differences between opaganib and placebo treatments. The
opaganib-treated group showed greater improvement in reducing
oxygen requirement by end of treatment at day 14 across key primary
and secondary efficacy outcomes.